ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
insight
/
details

Cell Therapy: Essential in Crafting Tailored Healthcare Approaches

NextEdge Admin

10 Jan 2024

3 min 17 sec

Cell therapy stands as a cornerstone of precision medicine, embodying personalized and targeted approaches to medical interventions. By harnessing the distinctive qualities of a patient’s cells, cell therapy aligns seamlessly with precision medicine’s principles.

Approved Cell Therapies:

CAR-T Cell Therapy:

Chimeric Antigen Receptor T-cell (CAR-T) therapy has attained regulatory approval for certain leukemia and lymphoma treatments. This approach involves modifying a patient’s T cells to express a receptor that targets cancer cells, showcasing the success of personalized immunotherapy in clinical applications.

Autologous Chondrocyte Implantation (ACI):

ACI, an established and approved treatment, exemplifies precision medicine in orthopedics. It involves harvesting and expanding a patient’s own cartilage cells for targeted regeneration, demonstrating the personalized nature of cell therapy.

Gene-Modified Hematopoietic Stem Cell Transplantation:

In certain genetic blood disorders, gene-modified hematopoietic stem cell transplantation has transitioned from research to approved treatments, showcasing the transformative impact of gene therapy in addressing the root causes of diseases.

2. Research and Investigational Areas:

Neural Stem Cell Therapy for Stroke:

Neural stem cell therapy for stroke represents an area of active research, with ongoing clinical trials exploring its potential. While not yet widely approved, this research holds promise for precisely addressing neurological conditions through regenerative approaches.

Cardiac Cell Therapy for Myocardial Infarction:

Cardiac cell therapy for myocardial infarction is predominantly in the research and clinical trial stage. The exploration of stem cells for cardiac regeneration exemplifies ongoing efforts to bring personalized precision medicine to heart disease treatment.

Dendritic Cell Vaccines for Cancer:

Dendritic cell vaccines for cancer remain in the research and clinical trial phase. This personalized immunotherapeutic approach is actively studied for its potential in stimulating immune responses against specific cancer cells.

Gene-Edited Mesenchymal Stem Cells for Genetic Bone Diseases:

The gene editing of mesenchymal stem cells for genetic bone diseases is primarily in the research and preclinical stage. This area showcases the evolving landscape of precision medicine, with investigations into gene-editing technologies for tailored therapeutic interventions